ReviewTransboundary and emerging diseases2026
Evolutionary and Spatiotemporal Dynamics of Foot-and-Mouth Disease Virus in Ethiopia (1957-2025): A Molecular Perspective on Serotype Persistence and Emergence.
Review in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot-and-mouth disease (FMD) represents a significant global economic burden and remains the primary constraint on Ethiopia's livestock economy and international trade. This desk review synthesized 60 years of data (1957-2025) using a structured, multidatabase search across four domains: disease, genotype/lineage, geographic spread, and temporal context. Data were stratified into three periods: Period I (1957-1980), Period II (1981-2000), and Period III (2001-2025). Results indicate that Period I saw the identification of serotypes O, A, and C, though serotype C has not been detected after 1983. Period II was marked by the continued circulation of serotypes O and A, and the first emergence of Serotype SAT 2 near the Kenya-Ethiopia border, which temporarily disappeared until its major re-emergence in 2007. Period III is characterized by a significant intensification and modernization of FMD virus (FMDV) outbreak investigation that provided more granular data on viral activity in the country. The period saw four major endemic serotypes O, A, SAT 2, and SAT 1, SAT one being confirmed for the first time during this period, circulate simultaneously and covering the entire country. Molecular analyses revealed a heterogeneous landscape: serotype O is dominated the serotype distribution in the country by its O/EA-3 and O/EA-4 topotypes, while serotype A involving complex lineages (Africa G-I, G-IV, and G-VII) follows in serotype O and precedes serotype SAT 2 in distribution. Notably, serotype SAT 2 has historically comprised four topotypes (IV, VII, XIII, and XIV), with the recent dominance of the re-emergent SAT 2/XIV topotype. The global biosecurity threat posed by FMDV SAT 2 topotype XIV stems from its unprecedented transcontinental dissemination into immunologically naive regions, rather than inherent lethality. This expansion highlights the complex evolutionary dynamics of the virus and the vulnerability of current surveillance system. The global dissemination of emerging lineages, such as SAT 2 topotype XIV, underscores the complex evolutionary dynamics and environmental plasticity inherent across all FMDV serotypes. The rapid shift of these viruses into nonendemic territories highlights critical vulnerabilities in existing biosecurity. Ultimately, these dynamics necessitate a shift toward adaptive, multiserotype surveillance and integrated control frameworks to address the continuous antigenic evolution and geographical expansion of the virus. Advancing Ethiopia along the progressive control pathway (PCP-FMD) is critically contingent upon evaluating the protective efficacy of current trivalent vaccines against rapidly evolving field strains. Immediate intervention is required to address diverged genotypes that jeopardize both national herd health and international market access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.